Memory awareness in patients with Major Depressive Disorder

Mendes, Tiago; Cardoso, Sandra; Guerreiro, Manuela; Marôco, João; Silva, Dina; Alves, Luísa; Schmand, Ben; Couto, Frederico Simões do; Figueira, Maria Luísa; Mendonça, Alexandre de

doi:10.1016/j.jpsychires.2021.03.016

Cited by 5 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Semkovska et al found that patients with MDD had impairments in logical and working memory during both phases of active symptoms and remission, and logical memory impairments were more severe ( 50 ). Mendes et al ( 51 ) also found that logical memory scores were lower in patients with MDD than in HCs, and logical memory scores did not recover to normal levels at the time of initial remission after antidepressant treatment ( 52 ). Interestingly, the present results showed that the LMT scores improved at 4 weeks of treatment and returned to the levels of the HCs after 8 weeks of treatment in the patients with MDD.…”

Section: Discussionmentioning

confidence: 99%

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine

Wang

Xiong

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

ObjectiveThis study aimed to explore both impairments in attention function in patients with major depressive disorder (MDD) and the efficacy of escitalopram monotherapy or combination therapy with agomelatine.MethodsA total of 54 patients with MDD and 46 healthy controls (HCs) were included. Patients were treated with escitalopram for 12 weeks; those who presented with severe sleep impairments were also given agomelatine. Participants were evaluated using the Attention Network Test (ANT), which included tests of alerting, orienting, and executive control networks. Concentration, instantaneous memory, and resistance to information interference were tested using the digit span test, and the logical memory test (LMT) was used to evaluate abstract logical thinking. The Hamilton Depression Rating Scale−17 items, Hamilton Anxiety Rating Scale, and Pittsburgh Sleep Quality Index were used to assess depression, anxiety, and sleep quality, respectively. Patients with MDD were assessed at the end of weeks 0, 4, 8, and 12. HCs were assessed once at baseline.ResultsCompared with HCs, patients with MDD showed significantly different alerting, orienting, and executive control functions of attention networks. Treatment with escitalopram alone or combined with agomelatine significantly improved LMT scores at the end of weeks 4, 8, and 12 and restored scores to the level of HCs at the end of week 8. Total Toronto Hospital Test of Alertness scores in patients with MDD increased significantly after 4 weeks of treatment. The ANT executive control reaction time in patients with MDD decreased significantly after 4 weeks of treatment, with this decrease lasting until the end of week 12, but scores did not return to the levels of HCs. Combined treatment with escitalopram and agomelatine led to more improvement in ANT orienting reaction time and was accompanied by a greater reduction of total scores on the Hamilton Depression Rating Scale−17 items and Hamilton Anxiety Rating Scale compared with escitalopram monotherapy.ConclusionsPatients with MDD showed overall impairments in three domains of attention networks as well as the LMT and a test of subjective alertness. Escitalopram monotherapy significantly improved the LMT scores and the executive control function scores in the ANT at the end of the fourth week of treatment, and the improvement was more extensive with combined escitalopram and agomelatine treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine

Wang

Xiong

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…At the same time, due to the learning and memory disorders in depression, 12 13 it is closely related to the qi and blood nutrition around the human body. 14 In the Medical Rules and Regulations(Yi Lin Sheng Mo) , it recorded that “the spirit depends on blood and qi of the body.…”

Section: Liver Depression and Spleen Deficiency Is The Main Pathogene...mentioning

confidence: 99%

Research Progress of the Liver–Brain Cotreatment of Depression with Supplemented Danzhi Xiaoyao Powder

Wang

Liu

Bai

et al. 2022

Chinese medicine and natural products

View full text Add to dashboard Cite

Traditional Chinese medicine (TCM) has unique advantages in preventing and treating depression based on holistic concepts and syndrome differentiation and treatment. Liver depression and spleen deficiency are the main syndrome of depression. Danzhi Xiaoyao powder has the efficacy of soothing the liver and relieving depression, nourishing blood, and strengthening spleen. Present studies have proven that it has antidepressant efficacy for the syndrome of liver depression and spleen deficiency. The basic research on pharmacodynamic substances has found that the main active ingredients of Danzhi Xiaoyao powder in the treatment of depression include bupleurum saponin, paeonol, gardenoside, angelica polysaccharide, sulfate polysaccharide, paeoniflorin, albiflorin, atractylone, etc. In clinical practice, Danzhi Xiaoyao powder is often modified to make it more suitable according to the characteristics of pathogenesis and changes in the disease condition. Our research group has found that “brain and spirit failure and liver failing to disperse” are the main pathogenesis of depression. Based on the theory of “liver–brain cotreatment,” the treatment principle of “dispersing the liver and relieving depression, strengthening brain and benefiting intelligence” was put forward. On the basis of Danzhi Xiaoyao powder, Shichangpu (Acori Tatarinowii Rhizoma) was added to enlighten the mind and Yuanzhi (Polygalae Radix) to calm the mind and benefit intelligence. The modified Danzhi Xiaoyao powder was formulated, and its clinical effects on depression were remarkable. Animal experiments also confirmed that modified Danzhi Xiaoyao powder can significantly improve the depression-like behavior of depression model rats and the mechanism may be related to the regulation of the hypothalamic–pituitary–adrenal axis, the increase of the content of 5-hydroxytryptamine, and norepinephrine, which provides a reference for the further promotion of the clinical application of modified Danzhi Xiaoyao powder in the treatment of depression.

show abstract

“…At the same time, due to the learning and memory disorders in depression, 12,13 it is closely related to the qi and blood nutrition around the human body. 14 In the Medical Rules and Regulations(Yi Lin Sheng Mo), it recorded that "the spirit depends on blood and qi of the body.…”

Section: Liver Depression and Spleen Deficiency Is The Main Pathogene...mentioning

confidence: 99%

Untitled

2022

Chinese medicine and natural products

View full text Add to dashboard Cite

Traditional Chinese medicine (TCM) has unique advantages in preventing and treating depression based on holistic concepts and syndrome differentiation and treatment. Liver depression and spleen deficiency are the main syndrome of depression. Danzhi Xiaoyao powder has the efficacy of soothing the liver and relieving depression, nourishing blood, and strengthening spleen. Present studies have proven that it has antidepressant efficacy for the syndrome of liver depression and spleen deficiency. The basic research on pharmacodynamic substances has found that the main active ingredients of Danzhi Xiaoyao powder in the treatment of depression include bupleurum saponin, paeonol, gardenoside, angelica polysaccharide, sulfate polysaccharide, paeoniflorin, albiflorin, atractylone, etc. In clinical practice, Danzhi Xiaoyao powder is often modified to make it more suitable according to the characteristics of pathogenesis and changes in the disease condition. Our research group has found that "brain and spirit failure and liver failing to disperse" are the main pathogenesis of depression. Based on the theory of "liver-brain cotreatment," the treatment principle of "dispersing the liver and relieving depression, strengthening brain and benefiting intelligence" was put forward. On the basis of Danzhi Xiaoyao powder, Shichangpu (Acori Tatarinowii Rhizoma) was added to enlighten the mind and Yuanzhi (Polygalae Radix) to calm the mind and benefit intelligence. The modified Danzhi Xiaoyao powder was formulated, and its clinical effects on depression were remarkable. Animal experiments also confirmed that modified Danzhi Xiaoyao powder can significantly improve the depression-like behavior of depression model rats and the mechanism may be related to the regulation of the hypothalamic-pituitary-adrenal axis, the increase of the content of 5hydroxytryptamine, and norepinephrine, which provides a reference for the further promotion of the clinical application of modified Danzhi Xiaoyao powder in the treatment of depression.

show abstract

Memory awareness in patients with Major Depressive Disorder

Cited by 5 publications

References 46 publications

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine

Research Progress of the Liver–Brain Cotreatment of Depression with Supplemented Danzhi Xiaoyao Powder

Untitled

Contact Info

Product

Resources

About